gitrabin 2000 mg prašak za otopinu za infuziju
teva b.v., swensweg 5, haarlem, nizozemska - gemcitabinklorid - prašak za otopinu za infuziju - 2000 mg - urbroj: svaka bočica sadrži 2000 mg gemcitabina (u obliku gemcitabinklorida)
protravis 40 mikrograma/ml kapi za oko, otopina
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - травопрост - kapi za oko, otopina - 40 mikrograma/ml - urbroj: svaki ml otopine sadrži 40 mikrograma travoprosta
lucentis 10 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - ranibizumab - rastvor za injekciju - 10 mg/1 ml - 1 ml rastvora za injekciju sadrži: 10 mg (2,3 mg/0,23 ml) ranibizumaba
bravis 10 mg/ml kapi za oko, suspenzija
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - brinzolamid - kapi za oko, suspenzija - 10 mg/ml - urbroj: jedan ml suspenzije sadrži 10 mg brinzolamida
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
azot suboksid messer 100 % v/v/1 inhalacija medicinski gas, djelimicno tečni
messer tehnoplin d.o.o - azot suboksid - medicinski gas, djelimicno tečni - 100 % v/v/1 inhalacija - medicinski gas, djelimično tečni sadrži 100 % (v/v) azotsuboksida
azot suboksid messer 100 % v/v/1 inhalacija medicinski gas, djelimicno tečni
messer tehnoplin d.o.o - azot suboksid - medicinski gas, djelimicno tečni - 100 % v/v/1 inhalacija - medicinski gas, djelimično tečni sadrži 100 % (v/v) azot suboksid
azot suboksid messer 100 % v/v/1 inhalacija medicinski gas, djelimicno tečni
messer tehnoplin d.o.o - azot suboksid - medicinski gas, djelimicno tečni - 100 % v/v/1 inhalacija - medicinski gas, djelimično tečni sadrži 100 % (v/v) azotsuboksid